We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the […]
The I-SPY2 trial (NCT01042379) is a multicentre, phase 2 trial where patients with HER2-negative breast cancer were randomized to receive neoadjuvant cemiplimab plus REGN3767 and paclitaxel or weekly paclitaxel for 12 cycles. In this touchONCOLOGY interview, we speak with Prof. Claudine Isaacs (Georgetown University, Washington, DC, USA) who gives an overview of the I-SPY2 study […]
The APT trial investigates adjuvant paclitaxel and trastuzumab in patients with node negative HER2+ breast cancer. Dr Sara Tolaney (Harvard Medical School, Boston, MA, USA) discusses the end-of-study, 10-year survival outcome results and explore what the study has demonstrated in terms of the role of the HER2DX genomic assay in predicting long-term outcomes (NCT00542451). The […]
The ACOSOG (Alliance) Z11102 (NCT01556243) phase II single arm prospective trial evaluated how well breast-conserving surgery and radiation therapy worked in treating patients with multiple ipsilateral breast cancer. In this touchONCOLOGY interview, we speak with Prof. Judy Boughey (Mayo Clinic, Rochester, MN, USA) who gives an overview on multiple ipsilateral breast cancer and also discusses […]
The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the […]
Complete remission rates are high for adults with acute lymphoblastic leukaemia (ALL), however, relapse is frequent and survival rates are poor even if the measurable residual disease (MRD) status is negative. In this touchONCOLOGY interview, we speak with Dr Mark Litzow (Mayo Clinic, Rochester, MN, USA) to discuss relapse rates and prognosis in patients with […]
The ECOG-ACRIN E1910 study assessed the benefit of blinatumomab for BCR::ABL1 negative B-lineage acute lymphoblastic leukaemia (ALL) patients who become measurable residual disease negative (<0.01%) after induction chemotherapy. In this touchONCOLOGY interview, we speak with Dr Mark Litzow (Mayo Clinic, Rochester, MN, USA) to discuss the findings of the study and their impact on the […]
Proton therapy is a form of radiation treatment that can precisely target and deliver high radiation doses to a tumour to kill cancerous cells. In this touchONCOLOGY interview, we speak with Dr Robert Mutter (Mayo Clinic Rochester, MN, United States) to tell us a little about proton therapy and its potential benefits in the treatment […]
The phase II randomized trial of conventional versus hypofractionated proton radiotherapy investigated whether condensing treatment to 15 fractions would be safe based on evidence that breast cancer is more sensitive to higher dose fractions than surrounding normal tissues. In this touchONCOLOGY interview, we speak with Dr Robert Mutter (Mayo Clinic Rochester, MN, United States) provides an overview of […]
Get the latest clinical insights from touchONCOLOGY